Share
Export Citation
Association of KRAS exon 2 mutation with clinicopathological aspects of colorectal cancer
Nurnaningsi T.
Gazzetta Medica Italiana Archivio Per Le Scienze Mediche
Q4Abstract
BACKGROUND: Colorectal cancer (CRC) poses a significant global health threat, ranking among the most prevalent cancers and causing many fatalities. Diet, lifestyle, and genetic mutations, notably KRAS, play pivotal roles in its development. Understanding the correlation between KRAS exon 2 mutations and clinicopathological aspects of CRC could offer insights for improved screening and preventive measures, potentially reducing the disease’s impact.METHODS: This observational study was performed from January to July 2023. KRAS exon 2 mutations were measured in 48 CRC patients (14 with KRAS exon 2 mutations and 34 without) using polymerase chain reaction (PCR) methods.RESULTS: The 48 CRC patients comprised 22 men (45.8%) and 26 women (54.2%), with an average age of 56-65 years. Ten (20.8%) had stage I CRC and eight (16.7%) had stage IV; as many as 33 (68.7%) had high-grade CRC. A significant relationship existed between age and KRAS exon 2 mutation status (P=0.045). No significant relationship existed between CRC stage and KRAS exon 2 mutation (P=3.934). A significant relationship was found between CRC histopathology grading and KRAS exon 2 mutation (P=0.046). A relationship existed between tumor location and KRAS exon 2 mutation (P=0.041). No relationship was found between blood type (A, B, AB) and KRAS exon 2 mutation (P=2.480). Of the 25 CRC tissue samples, PCR examination found KRAS exon 2 mutations in 11, as well as three positive samples among 23 rectal cancer samples.CONCLUSIONS: Significant associations existed between clinicopathological aspects and KRAS exon 2 mutation in CRC. These might be considered potential biomarkers of CRC.